Figure 7.

Effect of Amb4269951 on U251MG xenograft tumor progression and body weight. (A) The tumor volume was measured after intraperitoneal administration of 10 mg/kg Amb4269951 (n = 5) and the vehicle control with DMSO (n = 5). The date of administration is indicated by an arrow. (B) The Amb4269951 group significantly reduced xenograft tumor growth compared to the DMSO group (* p < 0.05). (C) The body weight of mice was measured at the time of drug administration. Data are represented as the mean ± SD (n = 5).